Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
94.45%
Operating Margin
35.13%
Net Margin
50.45%
Efficiency Metrics
Revenue per Expense Ratio
1.54
R&D as % of Revenue
19.62%
Earnings Quality
EBITDA Margin
43.41%
Income Tax Rate
9.98%
EPS
1.2200000000
Balance Sheet Analysis
Current Ratio
12.36
Cash Ratio
8.17
Working Capital
$17.54M
Debt to Equity
0.07
Debt to Assets
6.38%
Equity Ratio
87.91%
Cash Flow Analysis
Operating Cash Flow Ratio
41.72%
Free Cash Flow Ratio
41.67%
CapEx to Revenue
0.05%
Dividends Paid
$2.82M
Stock Buybacks
No buybacks
Total Shareholder Returns
$2.82M
Cash Position Change
452.76%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 8.42%
Increased R&D investment by 21.56%
Detailed Growth Metrics
Core Performance
Revenue
5.87%
Net Income
450.71%
EPS
454.55%
Operating Income
188.49%
Operational Efficiency
R&D Expenses
21.56%
SG&A Expenses
-9.35%
Operating Cash Flow
720.21%
Free Cash Flow
10,846.00%
Balance Sheet Health
Assets
21.55%
Debt
-2.50%
Book Value per Share
20.46%
Inventory
26.41%
Shareholder Returns
Dividends per Share
8.42%
Shares Outstanding
0.54%
Long Term Trends
3Y Revenue/Share
-2.44%
5Y Revenue/Share
-13.27%
3Y Dividend/Share
0.00%
5Y Dividend/Share
0.00%